Easl 2023 – GLP-1 combos take on a milder form of Nash
Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.
Obesity dropouts hurt Altimmune
The company’s value is cut in half as mid-stage data prove a let-down.
Altimmune aims to build Momentum in obesity
A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.
Catalysts ahead for the smaller players
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.